

August 12, 2020

To Listing Department, <b>NATIONAL STOCK EXCHANGE OF INDIA LIMITED</b> Exchange Plaza, Bandra Kurla Complex, Bandra (E), <b>MUMBAI -400 051</b> <b>Company Code No. AUOPHARMA</b>	To The Corporate Relations Department <b>BSE LIMITED</b> Phiroz Jeejeebhoy Towers, 25 <sup>th</sup> floor, Dalal Street, <b>MUMBAI -400 001</b> <b>Company Code No. 524804</b>
---	--

Dear Sir,

**Sub: Outcome of Board Meeting held on August 12, 2020.**

The Board of Directors of the Company at its meeting held today, August 12, 2020, has, inter alia, transacted the following businesses:

1. Approved the Un-audited Financial Results of the Company for the First Quarter ended June 30, 2020 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Un-audited Financial Results along with the Limited Review Reports of the Statutory Auditors of the Company.
2. Approved an Interim Dividend @ 125% i.e Rs.1.25 (Rupee one and paise twenty five) per equity share of Re.1/- each on the equity share capital of the Company for the Financial Year 2020-21.

Please refer to our letter dated August 3, 2020 wherein we have informed that the Register of Members and Share Transfer Books of the Company are being closed from **August 25, 2020 to August 27, 2020** (both days inclusive) for the purpose of 33<sup>rd</sup> Annual General Meeting of the Company. We hereby further inform that the aforesaid book closure dates will also be considered to determine the entitlement of the shareholders to the aforesaid interim dividend of 125% i.e Rs.1.25 (Rupee one and paise twenty five) per equity share of Re.1/- each on the equity share capital of the Company for the year 2020-21 as approved by the Board on August 12, 2020 and the same will be paid on or before **September 4, 2020**.

We also enclose a copy of the Press Release on Un-audited Financial Results of the Company for the First Quarter ended June 30, 2020.

The Board meeting commenced at 4.00 p.m. and concluded at 7.00 p.m.

Yours faithfully,

For **AUROBINDO PHARMA LIMITED**



B. Adi Reddy  
Company Secretary

Enclosures: as above.



**AUROBINDO PHARMA LIMITED**

(CIN : L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad - 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

Regd. Off.: Plot No. 2, Maithriviher, Ameerpet, Hyderabad - 500 038. T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

[www.aurobindo.com](http://www.aurobindo.com)

**AUROBINDO PHARMA LIMITED**  
(CIN - L24239TG1986PLC015190)

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500 038, India

Tel: +91 040 23736370; Fax: +91 40 23747340; Email: info@aurobindo.com

(Rs. In lakhs)

**STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2020**

Particulars	Quarter ended			Year ended
	30.06.2020	31.03.2020	30.06.2019	31.03.2020
	Unaudited	Audited	Unaudited	Audited
<b>1 Revenue from operations</b>				
(a) Net sales/ income from operations	333,725	353,428	299,703	1,293,453
(b) Other operating income	8,245	8,604	8,180	33,195
<b>Total revenue from operations</b>	<b>341,970</b>	<b>362,032</b>	<b>307,883</b>	<b>1,326,648</b>
<b>2 Other income</b>				
(a) Foreign exchange gain (net) (refer note 7)	5,211	4,793	2,474	8,941
(b) Others	7,347	11,268	540	16,860
<b>Total other income</b>	<b>12,558</b>	<b>16,061</b>	<b>3,014</b>	<b>25,801</b>
<b>Total income (1+2)</b>	<b>354,528</b>	<b>378,093</b>	<b>310,897</b>	<b>1,352,449</b>
<b>3 Expenses</b>				
(a) Cost of materials consumed	179,143	179,276	161,540	674,755
(b) Purchase of stock-in-trade	514	68	238	551
(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(38,086)	(12,692)	(7,572)	(22,953)
(d) Employee benefits expense	42,469	42,494	37,756	156,147
(e) Finance costs	1,043	1,746	3,195	9,558
(f) Depreciation and amortisation expense	11,979	11,885	11,515	47,048
(g) Other expenses	61,447	68,027	60,880	249,573
<b>Total expenses</b>	<b>258,509</b>	<b>290,804</b>	<b>267,552</b>	<b>1,114,679</b>
<b>4 Profit before tax (1+2-3)</b>	<b>96,019</b>	<b>87,289</b>	<b>43,345</b>	<b>237,770</b>
<b>5 Tax expense</b>				
Current tax	24,758	19,617	9,361	50,586
Tax credit - Minimum Alternate Tax (MAT)	-	-	(1,144)	-
Deferred tax	(207)	(4,832)	2,078	(90)
<b>Total tax expense</b>	<b>24,551</b>	<b>14,785</b>	<b>10,295</b>	<b>50,496</b>
<b>6 Profit for the period/year (4-5)</b>	<b>71,468</b>	<b>72,504</b>	<b>33,050</b>	<b>187,274</b>
<b>7 Other Comprehensive income</b>				
Items that will not to be reclassified subsequently to profit or loss:				
(a) Re-measurement of defined benefit liability	(482)	(837)	(55)	(1,929)
(b) Income-tax relating to items that will not be reclassified to profit or loss	169	292	19	674
<b>8 Total Comprehensive income for the period/year (6+7)</b>	<b>71,155</b>	<b>71,959</b>	<b>33,014</b>	<b>186,019</b>
<b>9 Paid-up equity share capital (face value Re. 1 per share)</b>	<b>5,859</b>	<b>5,859</b>	<b>5,859</b>	<b>5,859</b>
<b>10 Other equity</b>				<b>1,296,697</b>
<b>11 Earnings per equity share (face value Re. 1 per share)</b>	<b>(not annualised)</b>	<b>(not annualised)</b>	<b>(not annualised)</b>	<b>( annualised)</b>
(a) Basic (in Rs.)	12.20	12.37	5.64	31.96
(b) Diluted (in Rs.)	12.20	12.37	5.64	31.96



*Handwritten signature/initials*

**NOTES:**

- 1 The financial results of the Company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder.
- 2 The above standalone financial results as reviewed by the audit committee have been approved by the Board of Directors at its meeting held on 12 August 2020. The statutory auditors have carried out limited review of the above results for the quarter ended 30 June 2020. An unmodified report has been issued by them thereon.
- 3 The Company operates in only one segment viz., 'Pharmaceutical Products'.
- 4 Sales of standalone include exports of Rs.281,483 lakhs for the current quarter (30 June 2019: Rs.254,741 lakhs).
- 5 The Government of India, on 20 September 2019, vide the Taxation Laws (Amendment) Ordinance 2019, the Ordinance inserted a new Section 115BAA in the Income tax Act, 1961, which provides an option to the Company for paying income tax at reduced rates as per the provisions/conditions defined in the Said section. The Company has evaluated the above Ordinance and based on its evaluation currently the management proposed to continue with the old tax rates.
- 6 The joint petition seeking sanction of the Hon'ble National Company Law Tribunal, Hyderabad Bench (NCLT) for the Scheme of Amalgamation of APL Research Centre Limited, Aurozymes Limited, Curepro Parenterals Limited, Hyacinths Pharma Private Limited, Silicon Life Sciences Private Limited and APL Healthcare Limited (all wholly owned subsidiary companies) with the Company has been admitted. The matter listed for final hearing on 28 February 2020 was adjourned to 23 March 2020, but due to Covid - 19 as on the date of this report, the matter of sanction of the Scheme by NCLT continues to be pending.
- 7 Foreign exchange gain includes exchange difference arising from foreign currency borrowings to the extent that they are regarded as an adjustment to finance cost as per para 6(e) of Ind AS 23 on borrowing costs.
- 8 The Company continues to monitor the possible effects that may result from the pandemic relating to COVID-19. With a view to ensure minimal disruption with respect to operations including production and distribution activities, the Company has taken several business continuity measures. While the disruption has impacted overall sales due to logistical delays, considering that the Company deals with Pharmaceuticals drugs that are classified as essentials, the disruption with respect to Company's operation including production and distribution activities is not overall material. The Company has not experienced any significant difficulties with respect to market demand, financing capital expansion projects, collections or liquidity. Based on internal and external sources of information, current economic environment and future economic indicators, the Company has assessed the financial impact of the Covid 19 situation on its operations particularly on the carrying amounts of receivables, inventories, property, plant and equipment and intangible assets and concluded that the overall impact is not material. However, the impact of the pandemic could be different from those estimated today considering the uncertainties involved. The Company will continue to monitor any material changes to future economic conditions.
- 9 The figures of the quarter ended 31 March 2020 are the balancing figures between audited figures in respect of the full financial year upto 31 March 2020 and the unaudited published year to date figures upto 31 December 2019, being the date of the end of the third quarter of the financial year. The standalone results for the nine months ended 31 December 2019 have been subjected to the limited review by the statutory auditors
- 10 The Board has approved interim dividend @125% i.e.Re.1.25 (Rupee One and Twenty five paise only) per equity share of Re.1 (Rupee One only) for the year 2020-21.
- 11 Previous period figures have been regrouped/ rearranged wherever considered material and necessary to confirm to the current period presentation.



By Order of the Board

  
N. Govindarajan  
Managing Director  
DIN-00050482

Place: Hyderabad  
Date :12 August 2020

[www.aurobindo.com](http://www.aurobindo.com)



# B S R & Associates LLP

Chartered Accountants

Salarpuria Knowledge City  
Orwell, B Wing, 6th Floor, Unit - 3  
Sy No. 83/1, Plot No. 2, Raidurg  
Hyderabad - 500 081, India.

Telephone +91 40 7182 2000  
Fax +91 40 7182 2399

## **Independent Auditor's Review Report on unaudited quarterly standalone financial results under Regulation 33 of the Listing Regulations**

To  
The Board of Directors of  
Aurobindo Pharma Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results ("the Statement") of Aurobindo Pharma Limited ("the Company") for the quarter ended 30 June 2020.
2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that the figures for the 3 months ended 31 March 2020 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

**B S R & Associates LLP**

**Aurobindo Pharma Limited**  
**Review report (continued)**

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For B S R & Associates LLP**  
Chartered Accountants

Firm Registration Number: 116231W/W-100024

SRIRAM  
MAHALINGAM

Digitally signed by  
SRIRAM MAHALINGAM  
Date: 2020.08.12  
18:55:28 +05'30'

**Sriram Mahalingam**

Partner

Membership Number: 049642

UDIN: 20049642AAAAEE7461

Place: Hyderabad

Date: 12 August 2020

**AUROBINDO PHARMA LIMITED**

(CIN - L24239TG1986PLC015190)

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500 038, India

Tel: +91 040 23736370; Fax: +91 40 23747340; Email: info@aubindo.com

(Rs. In lakhs)

**STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2020**

Particulars	Quarter ended			Year ended
	30.06.2020	31.03.2020	30.06.2019	31.03.2020
	Unaudited	Audited	Unaudited	Audited
<b>1 Revenue from operations</b>				
(a) Net sales/ income from operations	583,523	606,340	535,684	2,273,795
(b) Other operating income	8,955	9,503	8,776	36,055
<b>Total revenue from operations</b>	<b>592,478</b>	<b>615,843</b>	<b>544,460</b>	<b>2,309,850</b>
<b>2 Other income</b>				
(a) Foreign exchange gain (net) (refer note 7)	2,222	-	478	-
(b) Others	9,337	3,259	1,100	8,620
<b>Total other income</b>	<b>11,559</b>	<b>3,259</b>	<b>1,578</b>	<b>8,620</b>
<b>Total income (1+2)</b>	<b>604,037</b>	<b>619,102</b>	<b>546,038</b>	<b>2,318,470</b>
<b>3 Expenses</b>				
(a) Cost of materials consumed	209,817	203,798	186,038	772,498
(b) Purchase of stock-in-trade	60,157	51,324	53,007	211,211
(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(29,234)	(4,785)	(9,191)	(10,186)
(d) Employee benefits expense	88,799	86,433	77,986	321,918
(e) Finance costs	2,107	3,183	4,989	15,977
(f) Foreign exchange loss (net) (refer note 7)	-	2,619	-	3,970
(g) Depreciation and amortisation expense	25,552	23,241	24,086	96,671
(h) Other expenses	137,204	144,832	121,980	527,979
<b>Total expenses</b>	<b>494,402</b>	<b>510,645</b>	<b>458,895</b>	<b>1,940,038</b>
<b>4 Profit before share of profit of joint ventures, exceptional items and tax (1+2-3)</b>	<b>109,635</b>	<b>108,457</b>	<b>87,143</b>	<b>378,432</b>
<b>5 Share of loss of joint ventures, net of tax</b>	<b>(1,200)</b>	<b>(1,931)</b>	<b>471</b>	<b>(1,517)</b>
<b>6 Profit before exceptional items and tax (4+5)</b>	<b>108,435</b>	<b>106,526</b>	<b>87,614</b>	<b>376,915</b>
<b>7 Exceptional items (refer note 4)</b>	<b>-</b>	<b>(1,225)</b>	<b>1,270</b>	<b>2,613</b>
<b>8 Profit before tax (6-7)</b>	<b>108,435</b>	<b>107,751</b>	<b>86,344</b>	<b>374,302</b>
<b>9 Tax expense</b>				
Current tax	36,773	32,955	20,669	95,695
Tax credit - Minimum Alternate Tax (MAT)	-	-	(1,144)	-
Deferred tax	(6,406)	(10,103)	3,251	(4,344)
<b>Total tax expense</b>	<b>30,367</b>	<b>22,852</b>	<b>22,776</b>	<b>91,351</b>
<b>10 Profit for the period/year (8-9)</b>	<b>78,068</b>	<b>84,899</b>	<b>63,568</b>	<b>282,951</b>
<b>11 Other Comprehensive Income</b>				
A) Items that will not be reclassified subsequently to profit or loss:				
i) Re-measurement of defined employee benefit liability	(482)	(860)	(55)	(1,958)
ii) Income-tax relating to items that will not be reclassified to profit or loss	169	288	19	672
B) Items that will be reclassified subsequently to profit or loss:				
i) Exchange differences on translating the financial statements of foreign operations	6,426	15,446	1,044	29,998
ii) Income-tax on items that will be reclassified subsequently to profit or loss	-	-	-	-
<b>Total other comprehensive income for the period/year (net of tax)</b>	<b>6,113</b>	<b>14,874</b>	<b>1,008</b>	<b>28,712</b>
<b>12 Total Comprehensive income for the period/year (net of tax) (10+11)</b>	<b>84,181</b>	<b>99,773</b>	<b>64,576</b>	<b>311,663</b>
<b>Attributable to:</b>				
Owners of the Parent Company	84,171	99,857	64,591	311,809
Non-controlling interest	10	(84)	(15)	(146)
<b>Out of total comprehensive income above,</b>				
<b>Profit for the year attributable to:</b>				
Owners of the Parent Company	78,058	84,983	63,583	283,097
Non-controlling interest	10	(84)	(15)	(146)
<b>Other comprehensive income attributable to:</b>				
Owners of the Parent Company	6,113	14,874	1,008	28,712
Non-controlling interest	-	-	-	-
<b>13 Paid-up equity share capital (face value Re. 1 per share)</b>	<b>5,859</b>	<b>5,859</b>	<b>5,859</b>	<b>5,859</b>
<b>14 Other equity</b>				<b>1,675,179</b>
<b>15 Earnings per equity share (face value Re. 1 per share)</b>	<b>(not annualised)</b>	<b>(not annualised)</b>	<b>(not annualised)</b>	<b>(annualised)</b>
(a) Basic (in Rs.)	13.32	14.50	10.85	48.32
(b) Diluted (in Rs.)	13.32	14.50	10.85	48.32



**NOTES:**

- 1 The financial results of the Group have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder.
- 2 The above consolidated financial results have been prepared in accordance with principles and procedures as set out in the Ind AS 110 on "Consolidated financial statements" and Ind AS 28 on "Investments in Associates and Joint ventures" notified under Section 133 of Companies Act, 2013 and Companies (Indian Accounting Standards) Rules, 2015, as amended.
- 3 The above consolidated financial results as reviewed by the audit committee have been approved by the Board of Directors at its meeting held on 12 August 2020. The statutory auditors have carried out limited review of the above results for quarter ended 30 June 2020. An unmodified report has been issued by them thereon.
- 4 Exceptional items for the previous period/year represent acquisition related costs.
- 5 The Group operates in only one segment viz., 'Pharmaceutical Products'.
- 6 During the quarter, Curateq Biologics Private limited, India, a wholly owned subsidiary was incorporated w.e.f. 25 April 2020.
- 7 Foreign exchange gain/loss includes exchange difference arising from foreign currency borrowings to the extent that they are regarded as an adjustment to finance cost as per para 6(e) of Ind AS 23 on borrowing costs.
- 8 The Government of India, on 20 September 2019, vide the Taxation Laws (Amendment) Ordinance 2019, the Ordinance inserted a new Section 115BAA in the Income tax Act, 1961, which provides an option to the Company for paying income tax at reduced rates as per the provisions/conditions defined in the said section. The Parent Company has evaluated the above Ordinance and based on its evaluation currently the management proposed to continue with the old tax rates.
- 9 The joint petition seeking sanction of the Hon'ble National Company Law Tribunal, Hyderabad Bench (NCLT) for the Scheme of Amalgamation of APL Research Centre Limited, Aurozymes Limited, Curepro Parenterals Limited, Hyacinths Pharma Private Limited, Silicon Life Sciences Private Limited and APL Healthcare Limited (all wholly owned subsidiary companies) with the Company has been admitted. The matter listed for final hearing on 28 February 2020 was adjourned to 23 March 2020, but due to Covid - 19 as on the date of this report, the matter of sanction of the Scheme by NCLT continues to be pending.
- 10 The Group continues to monitor the possible effects that may result from the pandemic relating to COVID-19. With a view to ensure minimal disruption with respect to operations including production and distribution activities, the Group has taken several business continuity measures. While the disruption has impacted overall sales due to logistical delays, considering that the Group deals with Pharmaceuticals drugs that are classified as essentials, the disruption with respect to Group's operation including production and distribution activities is not overall material. The Group has not experienced any significant difficulties with respect to market demand, financing capital expansion projects, collections or liquidity. Based on internal and external sources of information, current economic environment and future economic indicators, the Group has assessed the financial impact of the Covid 19 situation on its operations particularly on the carrying amounts of receivables, inventories, property, plant and equipment and intangible assets and concluded that the overall impact is not material. However, the impact of the pandemic could be different from those estimated today considering the uncertainties involved. The Group will continue to monitor any material changes to future economic conditions.
- 11 The figures of the quarter ended 31 March 2020 are the balancing figures between audited figures in respect of the full financial year upto 31 March 2020 and the unaudited published year to date figures upto 31 December 2019, being the date of the end of the third quarter of the financial year. The consolidated results for the nine months ended 31 December 2019 have been subjected to the limited review by the statutory auditors.
- 12 The Board has approved interim dividend @125% i.e.Re.1.25 (Rupee One and Twenty five paise only) per equity share of Re.1 (Rupee One only) for the year 2020-21.
- 13 Previous period figures have been regrouped/ rearranged wherever considered material and necessary to confirm to the current period presentation.

Place: Hyderabad  
Date :12 August 2020



www.aurobindo.com

By Order of the Board

  
N. Govindarajan  
Managing Director  
DIN-00050482



# B S R & Associates LLP

Chartered Accountants

Salarpuria Knowledge City  
Orwell, B Wing, 6th Floor, Unit - 3  
Sy No. 83/1, Plot No. 2, Raidurg  
Hyderabad - 500 081, India.

Telephone +91 40 7182 2000  
Fax +91 40 7182 2399

## Independent Auditor's Review Report on unaudited quarterly consolidated financial results under Regulation 33 of the Listing Regulations

To  
The Board of Directors of  
Aurobindo Pharma Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Aurobindo Pharma Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net loss after tax and total comprehensive loss of its joint ventures for the quarter ended 30 June 2020 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

Sl. No.	Name of the Component	Country	Relationship
1	APL Research Centre Limited	India	Subsidiary
2	APL Healthcare Limited	India	Subsidiary
3	Auronext Pharma Private Limited	India	Subsidiary
4	Silicon Life Sciences Private Limited	India	Subsidiary
5	Auro Peptides Limited	India	Subsidiary
6	APL Pharma Thai Limited	Thailand	Subsidiary



**B S R & Associates LLP**

**Aurobindo Pharma Limited  
Review Report (continued)**

Sl. No.	Name of the component	Country	Relationship
7	All Pharma (Shanghai) Trading Company Limited	China	Subsidiary
8	Aurobindo Pharma USA Inc.	USA	Subsidiary
9	Natrol LLC	USA	Subsidiary
10	Aurolife Pharma LLC	USA	Subsidiary
11	Auro Health LLC	USA	Subsidiary
12	Auromedics Pharma LLC	USA	Subsidiary
13	Auro AR LLC	USA	Subsidiary
14	Auro Vaccines LLC	USA	Subsidiary
15	Auro Logistics LLC	USA	Subsidiary
16	Auro Packaging LLC	USA	Subsidiary
17	Aurobindo Pharma Produtos Farmaceuticos Limitada	Brazil	Subsidiary
18	Helix Healthcare B.V.	The Netherlands	Subsidiary
19	Aurogen South Africa (Pty) Ltd	South Africa	Subsidiary
20	Aurobindo Pharma (Pty) Limited	South Africa	Subsidiary
21	Novagen Pharma (Pty) Limited	South Africa	Joint Venture
22	Auro Pharma Inc.	Canada	Subsidiary
23	Aurovida Farmaceutica SA DE CV	Mexico	Subsidiary
24	Aurobindo Pharma Japan K.K.	Japan	Subsidiary
25	Aurobindo Pharma Colombia S.A.S.	Colombia	Subsidiary
26	Agile Pharma B.V.	The Netherlands	Subsidiary
27	Arrow Generiques SAS	France	Subsidiary
28	1980 Puren Pharma GmbH (formerly Actavis Management GmbH)	Germany	Subsidiary
29	Puren Pharma GmbH & Co., KG (formerly Actavis Deutschland GmbH & Co., KG)	Germany	Subsidiary
30	Aurovitas Spain SA (formerly Actavis Spain S.A.)	Spain	Subsidiary
31	Aurobindo Pharma B.V. (formerly Actavis B.V.)	The Netherlands	Subsidiary
32	Aurex B.V. (formerly Pharmacin B.V.)	The Netherlands	Subsidiary
33	Aurobindo Pharma GmbH	Germany	Subsidiary
34	Laboratorios Aurobindo S.L.	Spain	Subsidiary
35	Aurobindo Pharma (Italia) S.r.l.	Italy	Subsidiary
36	Aurobindo Pharma (Romania) S.r.l.	Romania	Subsidiary
37	Pharmacin B.V. (formerly Aurex B.V.)	The Netherlands	Subsidiary
38	Aurobindo Pharma (Malta) Limited	Malta	Subsidiary
39	APL Swift Services (Malta) Limited	Malta	Subsidiary
40	Milpharm Limited	United Kingdom	Subsidiary
41	Aurovitas Pharma Polska Sp, z.o.o.	Poland	Subsidiary
42	Generis Farmaceutica S.A.	Portugal	Subsidiary
43	Generis Phar, Unipessoal Lda.	Portugal	Subsidiary
44	Aurobindo Pharma Saudi Arabia Limited Company	Saudi Arabia	Subsidiary
45	Aurobindo Pharma Industria Farmaceutica Ltda	Brazil	Subsidiary
46	Hyacinths Pharma Private Limited	India	Subsidiary
47	Raidurgam Developers Limited (formerly Aurobindo Antibiotics Ltd)	India	Joint Venture
48	AuroZymes Limited	India	Subsidiary
49	Curepro Parenterals Limited	India	Subsidiary
50	Eugia Pharma Specialities Limited	India	Joint Venture
51	Tergene Biotech Private Limited	India	Joint Venture
52	Auro Pharma India Private Limited	India	Subsidiary
53	Aurovitas Pharma Ceska republika s.r.o.	Czech Republic	Subsidiary

**B S R & Associates LLP****Aurobindo Pharma Limited  
Review Report (continued)**

Sl. No.	Name of the Component	Country	Relationship
54	Aurovitas Pharma (Taizhou) Ltd	China	Subsidiary
55	Acrotech Biopharma LLC	USA	Subsidiary
56	Purple Bellflower (Pty) Ltd	South Africa	Joint Venture
57	Auroscience (Pty) Ltd	Australia	Subsidiary
58	Auro Science LLC	USA	Subsidiary
59	Apotex Nederland BV.	The Netherlands	Subsidiary
60	Aurovitas spol s.r.o (Formerly known as Apotex (CR) spol s.r.o)	Czech Republic	Subsidiary
61	Apotex N.V.	Belgium	Subsidiary
62	Apotex Europe BV	The Netherlands	Subsidiary
63	Sameko Farma B.V.	The Netherlands	Subsidiary
64	Leidapharm B.V.	The Netherlands	Subsidiary
65	Marel B.V.	The Netherlands	Subsidiary
66	Pharma Dossier B.V.	The Netherlands	Subsidiary
67	Aurobindo Pharma FZ LLC	U.A.E.	Subsidiary
68	Curateq Biologics GmbH	Switzerland	Subsidiary
69	Luoxin Aurovitas Pharm (Chengdu) Co., Ltd.	China	Joint Venture
70	Auroactive Pharma Pvt Ltd	India	Subsidiary
71	Aurobindo N.V, Belgium	Belgium	Subsidiary
72	Longxiang Pharma Taizhou Co., Ltd	China	Joint Venture
73	Novagen BBBEE Invest Co (Pty) Ltd	South Africa	Joint Venture
74	Curateq Biologics Private Limited (w.e.f. April 25, 2020)	India	Subsidiary

5. Attention is drawn to the fact that the figures for the 3 months ended 31 March 2020 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
7. We did not review the interim financial information of 8 subsidiaries included in the Statement, whose interim financial information reflect total revenues (including other income) (before consolidation adjustments) of Rs. 93,715 lakhs, total net profit after tax (before consolidation adjustments) of Rs. 7,448 lakhs and total comprehensive income (before consolidation adjustments) of Rs. 7,448 lakhs for the quarter ended 30 June 2020 as considered in the consolidated unaudited financial results. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

B S R & Associates LLP

**Aurobindo Pharma Limited**  
**Review Report (continued)**

Certain of these subsidiaries are located outside India whose financial results and other financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been reviewed by other auditors under generally accepted auditing standards applicable in their respective countries. The Parent's Management has converted the interim financial information of such subsidiaries located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have reviewed these conversion adjustments, if any made by the Parent's Management. Our conclusion in so far on the statement as it relates to the balances and affairs of such subsidiaries located outside India is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matters.

8. The Statement includes the interim financial information of 46 subsidiaries which have not been reviewed, whose interim financial information reflect total revenue (including other income) (before consolidation adjustments) of Rs. 133,080 lakhs, total net profit after tax (before consolidation adjustments) of Rs. 1,165 lakhs and total comprehensive income (before consolidation adjustments) of Rs. 1,165 lakhs for the quarter ended 30 June 2020, respectively, as considered in the Statement. The Statement also includes the Group's share of net loss after tax (before consolidation adjustments) of Rs. 1,256 lakhs and total comprehensive loss (before consolidation adjustments) of Rs. 1,256 lakhs for the quarter ended 30 June 2020, respectively, as considered in the consolidated unaudited financial results, in respect of 8 joint ventures, based on their interim financial information which have not been reviewed. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.

**For B S R & Associates LLP**  
Chartered Accountants  
Firm Registration No: 116231W/W-100024

SRIRAM  
MAHALINGAM

Digitally signed by SRIRAM  
MAHALINGAM  
Date: 2020.08.12 18:57:00 +05'30'

**Sriram Mahalingam**  
Partner  
Membership Number: 049642  
UDIN: 20049642AAAAEF6661

Place: Hyderabad  
Date: 12 August 2020



## NEWS RELEASE

12<sup>th</sup> Aug 2020, Hyderabad, India

### **Aurobindo Pharma Ltd Q1 FY21 Consolidate Financial Results**

Amount in INR Cr	Q1 FY20-21	Q1 FY19-20	% Chg	Q4 FY19-20	% Chg
Revenue from Operations	5,924.8	5,444.6	8.8	6,158.4	-3.8
EBITDA before Forex and Other income	1,257.4	1,146.4	9.7	1,342.4	-6.3
EBITDA %	21.2%	21.1%		21.8%	
PBT before Forex and Exceptional Items	1,074.1	866.7	23.9	1,110.8	-3.3
Net Profit after JV share, minority interest	780.6	635.8	22.8	849.8	-8.2

### **Key Highlights of Q1FY21 consolidated financials**

- Revenue from Operations at INR 5,924.8 Cr, witnessed a growth of 8.8% over corresponding previous period
  - US formulation revenue of INR 3,107.1 Cr vs INR 2,688.4 Cr in Q1FY20, registering a growth of 15.6% YoY
  - Europe formulation revenue at INR 1,322.2 Cr, a decline of 5.0% against Q1 last year
  - Growth Markets revenue declined by 7.6% YoY to INR 289.6 Cr
  - ARV revenue at INR 425.5 Cr vs. INR 318.5 Cr, an increase of 33.6% over corresponding previous period
  - API revenue for the quarter was at INR 780.2 Cr, an increase by 6.5% over corresponding previous period
- EBITDA before Forex and Other income at INR 1,257.4 Cr vs INR 1,146.4 Cr in Q1 last year, grew by 9.7%; EBITDA margin for the quarter was at 21.2%
- Net Profit after JV share, minority interest at INR 780.6 Cr as against INR 635.8 Cr in the corresponding previous period, witnessing a growth of 22.8% YoY.
- Basic & Diluted EPS is INR 13.32 per share.
- Research & Development (R&D) spend at INR 254.5 Cr, 4.3% of revenues
- Received final approval for 10 ANDAs from USFDA
- Interim Dividend @ 125% i.e., INR 1.25 per equity share of INR 1/- has been approved by the Board for FY20-21

**Commenting on the Company's performance, Mr. N. Govindarajan, Managing Director of the company said:** *"Amidst challenging times, we have started the financial year by reporting a healthy performance. We have ensured the business continuity without compromising the safety and well-being of our employees. We are committed to adhere to quality standards by investing continuously and developing a differentiated product pipeline for a sustainable growth"*

## **AUROBINDO PHARMA LIMITED**

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com



[www.aurobindo.com](http://www.aurobindo.com)

### Operational Performance (Consolidated):

Amount in INR Cr	Q1 FY20-21	Q1 FY19-20	% Chg	Q4 FY19-20	% Chg
<b>Formulations</b>					
USA	3,107.1	2,688.4	15.6	2,990.3	3.9
Europe	1,322.2	1,391.6	-5.0	1,652.5	-20.0
Growth Markets	289.6	313.4	-7.6	376.6	-23.1
ARV	425.5	318.5	33.6	381.8	11.5
<b>Total Formulations</b>	<b>5,144.3</b>	<b>4,712.0</b>	<b>9.2</b>	<b>5,401.2</b>	<b>-4.8</b>
<b>Active Pharmaceuticals Ingredients (API)</b>					
Betalactum	500.3	431.0	16.1	539.2	-7.2
Non Betalactum	279.8	301.2	-7.1	216.4	29.3
<b>Total API</b>	<b>780.2</b>	<b>732.2</b>	<b>6.5</b>	<b>755.6</b>	<b>3.3</b>
<b>Consolidated Sales</b>	<b>5,924.5</b>	<b>5,444.2</b>	<b>8.8</b>	<b>6,156.7</b>	<b>-3.8</b>
Dossier Income	0.3	0.4		1.7	
<b>Revenue from Operations</b>	<b>5,924.8</b>	<b>5,444.6</b>	<b>8.8</b>	<b>6,158.4</b>	<b>-3.8</b>

### **Consolidated Revenue breakup - Geography & segment wise**

#### Q1FY21



### Formulations

Formulation revenue for the quarter recorded a growth of 9.2% YoY to INR 5,144.3 Cr and accounted for 86.8% of total revenues.

#### **US Formulations**

- US revenue in Q1FY21 witnessed a growth of 15.6% YoY to INR 3,107.1 crore, accounting 52.4% of consolidated revenue. On constant currency basis, revenue grew by 6.5% YoY
- Filed 14 ANDAs with USFDA including 3 injectables in Q1FY21
- Received final approval for 10 ANDAs in Q1FY21

## **AUROBINDO PHARMA LIMITED**

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

[www.aurobindo.com](http://www.aurobindo.com)

- As on 30<sup>th</sup> June 2020, on a cumulative basis, the company filed 604 ANDAs with USFDA and received approval for 438 ANDAs including 28 tentative\* approvals
- The company has launched 6 products during the quarter including 1 injectable

\*Tentative approvals include 8 ANDAs approved under PEPFAR.

### Europe Formulations

- Europe revenue in Q1FY21 declined by 5.0% YoY to INR 1,322.2 crore, accounting 22.3% of consolidated revenue. In Euro terms, revenue declined by 10.6% YoY. Europe had witnessed stocking up at the beginning of the pandemic in Q4FY20.
- During 1<sup>st</sup> half of the current calendar year (CY20), Europe revenue posted a growth of 10.0% over last year corresponding period. In Euro terms, the revenues grew by 7.0% YoY basis.

### ARV Formulations

- ARV business revenue for Q1FY21 was at INR 425.5 Cr compared to INR 318.5 Cr in Q1FY20, an increase of 33.6% YoY and accounted for 7.2% of revenue

### Growth Markets Formulations

- Revenue from Growth markets formulations in Q1FY21 declined by 7.6% YoY to INR 289.6 Cr and accounted for 4.9% of revenue. Growth Markets had witnessed stocking up at the beginning of the pandemic in Q4FY20.
- During 1<sup>st</sup> half of the current calendar year (CY20), Growth Markets revenue posted a growth of 10.8% over last year corresponding period. On constant currency basis, Growth Markets reported a growth of 4.7% on YoY basis

### API business

- In Q1FY21, API business posted a revenue of INR 780.2 Cr, an increase of 6.5% YoY and contributed 13.2% to the consolidated revenues
- The company filed 3 DMFs with USFDA during the quarter.

### Global Regulatory Filings:

Filings	Q1 FY20-21	Cumulative Filings as on 30 <sup>th</sup> June 2020
ANDAs (including filings made from Aurobindo USA)	14	604
DMFs (including filings made from AuroNext and AuroPeptide)	3	257
Formulations Dossiers in other key advanced markets (incl. Multiple registrations into Europe. South Africa and Canada) @	-	3,727
API DMF/COS filings in other key regulated markets (incl. Multiple registrations)	41	3,145

@The number of filings have come down from 3,810 as on 31<sup>st</sup> Mar 2020 due to SAHPRA backlog clearance program. As per the program, long awaiting pending dossiers are now resubmitted and some of the dossiers are withdrawn.

## AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

[www.aurobindo.com](http://www.aurobindo.com)



## **USFDA Approvals Received in Q1FY20-21**

### **Final Approvals**

<b>S No</b>	<b>Product</b>	<b>Therapy</b>
1	Cisatracurium Besylate (gNimbex) Inj 2mg/ml	Nondepolarizing skeletal muscle relaxant
2	Dexamethasone Sodium Phosphate(gHexadrol) Inj 10mg/ml	Steroid
3	Albuterol Sulfate Inhalation (gAccuNeb) Sol 0.63 mg/3 ml and 1.25mg/3ml	Respiratory
4	Azelastine Hydrochloride (gAstelin) Nasal Spray 137 mcg/0.1%	Anti-Histamine
5	Fluoxetine Hydrochloride (gProzac) Tab 10mg and 20mg	CNS
6	Fluoxetine Tab 60mg	CNS
7	Minocycline Hydrochloride Tab 50mg, 75mg and 100mg	Anti-Infective
8	Flucytosine Cap (gAncobon) 250 mg and 500mg	Anti-Fungal
9	Albuterol Sulfate Tab (gProventil) 2mg and 4mg	Respiratory
10	Ibuprofen Tab (gMotrin) 400mg, 600mg and 800 mg	Pain Relief

### **Earnings call details**

The company will host an earnings call at 8.30 AM IST on August 13<sup>th</sup>, 2020, to discuss the performance and answer any questions from participants.

Participants can dial-in on the numbers below

Primary Number: +91 22 6280 1437 / +91 22 7115 8825

Local Access Number: +91 70456 71221 (Available all over India)

### **About Aurobindo Pharma Limited:**

Aurobindo Pharma Limited (www.aurobindo.com), (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP:IN) headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, EU, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retroviral, CVS, CNS, Gastroenterological, Pain management and Anti-Allergic, supported by an outstanding R&D set-up. The Company is marketing these products globally in over 150 countries.

### **For further information, please contact:**

Krishna Kiran

Investor Relations

Phone: 040-66725401 / 66725000

Mobile: +91 98486 67906

Email: ir@aurobindo.com

## **AUROBINDO PHARMA LIMITED**

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

[www.aurobindo.com](http://www.aurobindo.com)

**Disclaimer:**

This press release contain statements that may constitute “forward looking statements” including and without limitation, statements relating to product characteristics and uses, sales potential and target dates for product launch, implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward looking statements represent our judgment and future expectations concerning the development of our business, a number of risks, uncertainties and other factors could cause actual developments and results to differ materially from our expectations. The company undertakes no obligation to publicly revise any forward looking statements to reflect future events or circumstances and will not be held liable for any use of this information.

**AUROBINDO PHARMA LIMITED**

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

**Corp off.:** The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059**Regd. Off. :** Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : [info@aurobindo.com](mailto:info@aurobindo.com)[www.aurobindo.com](http://www.aurobindo.com)

**AUROBINDO PHARMA LIMITED**  
(CIN - L24239TG1986PLC015190)

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500 038, India

Tel: +91 040 23736370; Fax: +91 40 23747340; Email: info@aurobindo.com

(Rs. In lakhs)

**STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2020**

Particulars	Quarter ended		Year ended	
	30.06.2020	31.03.2020	30.06.2019	31.03.2020
	Unaudited	Audited	Unaudited	Audited
<b>1 Revenue from operations</b>				
(a) Net sales/ income from operations	5,83,523	6,06,340	5,35,684	22,73,795
(b) Other operating income	8,955	9,503	8,776	36,055
<b>Total revenue from operations</b>	<b>5,92,478</b>	<b>6,15,843</b>	<b>5,44,460</b>	<b>23,09,850</b>
<b>2 Other income</b>				
(a) Foreign exchange gain (net) (refer note 7)	2,222	-	478	-
(b) Others	9,337	3,259	1,100	8,620
<b>Total other income</b>	<b>11,559</b>	<b>3,259</b>	<b>1,578</b>	<b>8,620</b>
<b>Total income (1+2)</b>	<b>6,04,037</b>	<b>6,19,102</b>	<b>5,46,038</b>	<b>23,18,470</b>
<b>3 Expenses</b>				
(a) Cost of materials consumed	2,09,817	2,03,798	1,86,038	7,72,498
(b) Purchase of stock-in-trade	60,157	51,324	53,007	2,11,211
(c) Changes in inventories of finished goods, stock-in-trade and work-in-	(29,234)	(4,785)	(9,191)	(10,186)
(d) Employee benefits expense	88,799	86,433	77,986	3,21,918
(e) Finance costs	2,107	3,183	4,989	15,977
(f) Foreign exchange loss (net) (refer note 7)	-	2,619	-	3,970
(g) Depreciation and amortisation expense	25,552	23,241	24,086	96,671
(h) Other expenses	1,37,204	1,44,832	1,21,980	5,27,979
<b>Total expenses</b>	<b>4,94,402</b>	<b>5,10,645</b>	<b>4,58,895</b>	<b>19,40,038</b>
<b>4 Profit before share of profit of joint ventures, exceptional items and tax (1+2-3)</b>	<b>1,09,635</b>	<b>1,08,457</b>	<b>87,143</b>	<b>3,78,432</b>
<b>5 Share of loss of joint ventures, net of tax</b>	<b>(1,200)</b>	<b>(1,931)</b>	<b>471</b>	<b>(1,517)</b>
<b>6 Profit before exceptional items and tax (4+5)</b>	<b>1,08,435</b>	<b>1,06,526</b>	<b>87,614</b>	<b>3,76,915</b>
<b>7 Exceptional items (refer note 4)</b>	<b>-</b>	<b>(1,225)</b>	<b>1,270</b>	<b>2,613</b>
<b>8 Profit before tax (6-7)</b>	<b>1,08,435</b>	<b>1,07,751</b>	<b>86,344</b>	<b>3,74,302</b>
<b>9 Tax expense</b>				
Current tax	36,773	32,955	20,669	95,695
Tax credit - Minimum Alternate Tax (MAT)	-	-	(1,144)	-
Deferred tax	(6,406)	(10,103)	3,251	(4,344)
<b>Total tax expense</b>	<b>30,367</b>	<b>22,852</b>	<b>22,776</b>	<b>91,351</b>
<b>10 Profit for the period/year (8-9)</b>	<b>78,068</b>	<b>84,899</b>	<b>63,568</b>	<b>2,82,951</b>
<b>11 Other Comprehensive Income</b>				
A) Items that will not be reclassified subsequently to profit or loss:				
i) Re-measurement of defined employee benefit liability	(482)	(860)	(55)	(1,958)
ii) Income-tax relating to items that will not be reclassified to profit or loss	169	288	19	672
B) Items that will be reclassified subsequently to profit or loss:				
i) Exchange differences on translating the financial statements of foreign operations	6,426	15,446	1,044	29,998
ii) Income-tax on items that will be reclassified subsequently to profit or loss	-	-	-	-
<b>Total other comprehensive income for the period/year (net of tax)</b>	<b>6,113</b>	<b>14,874</b>	<b>1,008</b>	<b>28,712</b>
<b>12 Total Comprehensive income for the period/year (net of tax) (10+11)</b>	<b>84,181</b>	<b>99,773</b>	<b>64,576</b>	<b>3,11,663</b>
<b>Attributable to:</b>				
Owners of the Parent Company	84,171	99,857	64,591	3,11,809
Non-controlling interest	10	(84)	(15)	(146)
<b>Out of total comprehensive income above,</b>				
<b>Profit for the year attributable to:</b>				
Owners of the Parent Company	78,058	84,983	63,583	2,83,097
Non-controlling interest	10	(84)	(15)	(146)
<b>Other comprehensive income attributable to:</b>				
Owners of the Parent Company	6,113	14,874	1,008	28,712
Non-controlling interest	-	-	-	-
<b>13 Paid-up equity share capital (face value Re. 1 per share)</b>	<b>5,859</b>	<b>5,859</b>	<b>5,859</b>	<b>5,859</b>
<b>14 Other equity</b>				<b>16,75,179</b>
<b>15 Earnings per equity share (face value Re. 1 per share)</b>	<b>not annualised</b>	<b>not annualised</b>	<b>not annualised</b>	<b>(annualised)</b>
(a) Basic (in Rs.)	13.32	14.50	10.85	48.32
(b) Diluted (in Rs.)	13.32	14.50	10.85	48.32

## AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

**Corp off.:** The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

**Regd. Off. :** Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

[www.aurobindo.com](http://www.aurobindo.com)



## NOTES:

- 1 The financial results of the Group have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder.
- 2 The above consolidated financial results have been prepared in accordance with principles and procedures as set out in the Ind AS 110 on "Consolidated financial statements" and Ind AS 28 on "Investments in Associates and Joint ventures" notified under Section 133 of Companies Act, 2013 and Companies (Indian Accounting Standards) Rules, 2015, as amended.
- 3 The above consolidated financial results as reviewed by the audit committee have been approved by the Board of Directors at its meeting held on 12 August 2020. The statutory auditors have carried out limited review of the above results for quarter ended 30 June 2020. An unmodified report has been issued by them thereon.
- 4 Exceptional items for the previous period/year represent acquisition related costs.
- 5 The Group operates in only one segment viz., 'Pharmaceutical Products'.
- 6 During the quarter, Curateq Biologics Private limited, India, a wholly owned subsidiary was incorporated w.e.f. 25 April 2020.
- 7 Foreign exchange gain/loss includes exchange difference arising from foreign currency borrowings to the extent that they are regarded as an adjustment to finance cost as per para 6(e) of Ind AS 23 on borrowing costs.
- 8 The Government of India, on 20 September 2019, vide the Taxation Laws (Amendment) Ordinance 2019, the Ordinance inserted a new Section 115BAA in the Income tax Act, 1961, which provides an option to the Company for paying income tax at reduced rates as per the provisions/conditions defined in the said section. The Parent Company has evaluated the above Ordinance and based on its evaluation currently the management proposed to continue with the old tax rates.
- 9 The joint petition seeking sanction of the Hon'ble National Company Law Tribunal, Hyderabad Bench (NCLT) for the Scheme of Amalgamation of APL Research Centre Limited, Aurozymes Limited, Curepro Parenterals Limited, Hyacinths Pharma Private Limited, Silicon Life Sciences Private Limited and APL Healthcare Limited (all wholly owned subsidiary companies) with the Company has been admitted. The matter listed for final hearing on 28 February 2020 was adjourned to 23 March 2020, but due to Covid - 19 as on the date of this report, the matter of sanction of the Scheme by NCLT continues to be pending.
- 10 The Group continues to monitor the possible effects that may result from the pandemic relating to COVID-19. With a view to ensure minimal disruption with respect to operations including production and distribution activities, the Group has taken several business continuity measures. While the disruption has impacted overall sales due to logistical delays, considering that the Group deals with Pharmaceuticals drugs that are classified as essentials, the disruption with respect to Group's operation including production and distribution activities is not overall material. The Group has not experienced any significant difficulties with respect to market demand, financing capital expansion projects, collections or liquidity. Based on internal and external sources of information, current economic environment and future economic indicators, the Group has assessed the financial impact of the Covid 19 situation on its operations particularly on the carrying amounts of receivables, inventories, property, plant and equipment and intangible assets and concluded that the overall impact is not material. However, the impact of the pandemic could be different from those estimated today considering the uncertainties involved. The Group will continue to monitor any material changes to future economic conditions.
- 11 The figures of the quarter ended 31 March 2020 are the balancing figures between audited figures in respect of the full financial year upto 31 March 2020 and the unaudited published year to date figures upto 31 December 2019, being the date of the end of the third quarter of the financial year. The consolidated results for the nine months ended 31 December 2019 have been subjected to the limited review by the
- 12 Previous period figures have been regrouped/ rearranged wherever considered material and necessary to confirm to the current period

By Order of the Board

Place: Hyderabad  
Date :12 August 2020

[www.aurobindo.com](http://www.aurobindo.com)

N. Govindarajan  
Managing Director  
DIN-00050482

## AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : [info@aurobindo.com](mailto:info@aurobindo.com)

[www.aurobindo.com](http://www.aurobindo.com)